Eisai to divest rights to anti epileptic Fycompa in the US to Catalyst Pharmaceuticals.
Eisai Co., Ltd. announced that it has entered into an agreement to transfer the United States (U.S.) commercial rights for the anti-epileptic drug (AED) Fycompa; (generic name: perampanel) CIII to Catalyst Pharmaceuticals, Inc., as well as to provide Catalyst Pharmaceuticals with an exclusive negotiation period for an asset in Eisai’s epilepsy pipeline
Eisai will maintain its rights to Fycompa in countries and regions outside the U.S. and continue to contribute to patients with epilepsy. Closing of the transaction is contingent on completion of review under antitrust laws in the U.S.
The agreement will provide the opportunity for Eisai’s neuroscience team to focus on its long-term strategic priorities on the research, development, and commercialization of its Alzheimer’s disease portfolio. Eisai remains committed to drug discovery and research for anti-epileptogenesis through the modulation of neuroinflammation or lipid metabolism in glia cells, as well as the application of new technologies including spatial RNA-sequence. Research is a crucial aspect of Eisai’s aim to gain a deeper understanding of human brain biology and technologies that may also ultimately lead to broader neuroscience discoveries.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.